Medical Innovations | Novartis

Press Release
Aug 30, 2025

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Press Release
Aug 18, 2025

New Novartis ESC data highlights strength of cardiovascular portfolio
Press Release
Jul 17, 2025

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Press Release
Jul 17, 2025

Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
Press Release
May 27, 2025

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Press Release
Apr 29, 2025

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Press Release
Apr 29, 2025

Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
Press Release
Mar 31, 2025

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
Press Release
Mar 21, 2025

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Press Release
Jan 31, 2025

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Press Release
Jan 31, 2025

Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
Press Release
Oct 29, 2024

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance